Uniqure NV vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Uniqure NV (QURE)

Q2 202617 Jun – 19 Jun 2026

▲3

FDA Reversal on AMT-130 Data Ignites 81% Surge and Analyst Upgrades

FDA accepts Phase I/II data for accelerated approval The FDA reversed its earlier stance and agreed that three-year data from the Phase I/II study of AMT-130 can be the main basis for a Biologics License Application. This removes a major regulatory hurdle, making approval much more likely and sending QURE up 81%.
This is the core new event that directly caused the stock's massive jump and changes the company's outlook.
BLA submission planned for Q3 2026 uniQure now plans to file for approval in the third quarter of 2026, a concrete near-term step. This gives investors a clear timeline and raises confidence that the therapy could reach the market sooner than expected.
It provides a specific catalyst date and shows the company is moving quickly toward commercialization.
Analyst upgrades and fair value increase Several Wall Street firms raised price targets, with Barclays and Cantor Fitzgerald upgrading to Overweight. The modelled fair value rose 35% to about $52.56, reflecting a potential $3 billion-plus peak sales opportunity for AMT-130.
Analyst actions and valuation changes show professional investors see significantly more upside after the FDA news.
Remaining execution risks and confirmatory study Despite the rally, Goldman Sachs kept a Neutral rating, noting that the FDA will still hold a meeting to discuss the design of a confirmatory study and that durability data are needed. These steps could delay or complicate final approval.
It provides a balanced view by highlighting that not all uncertainty is removed, which could cap further gains.

June 202617 Jun – 19 Jun 2026

▲3

FDA Reversal on AMT-130 Data Ignites 81% Surge and Analyst Upgrades

FDA accepts Phase I/II data for accelerated approval The FDA reversed its earlier stance and agreed that three-year data from the Phase I/II study of AMT-130 can be the main basis for a Biologics License Application. This removes a major regulatory hurdle, making approval much more likely and sending QURE up 81%.
This is the core new event that directly caused the stock's massive jump and changes the company's outlook.
BLA submission planned for Q3 2026 uniQure now plans to file for approval in the third quarter of 2026, a concrete near-term step. This gives investors a clear timeline and raises confidence that the therapy could reach the market sooner than expected.
It provides a specific catalyst date and shows the company is moving quickly toward commercialization.
Analyst upgrades and fair value increase Several Wall Street firms raised price targets, with Barclays and Cantor Fitzgerald upgrading to Overweight. The modelled fair value rose 35% to about $52.56, reflecting a potential $3 billion-plus peak sales opportunity for AMT-130.
Analyst actions and valuation changes show professional investors see significantly more upside after the FDA news.
Remaining execution risks and confirmatory study Despite the rally, Goldman Sachs kept a Neutral rating, noting that the FDA will still hold a meeting to discuss the design of a confirmatory study and that durability data are needed. These steps could delay or complicate final approval.
It provides a balanced view by highlighting that not all uncertainty is removed, which could cap further gains.

Latest17 Jun – 19 Jun 2026

▲3

FDA Reversal on AMT-130 Data Ignites 81% Surge and Analyst Upgrades

FDA accepts Phase I/II data for accelerated approval The FDA reversed its earlier stance and agreed that three-year data from the Phase I/II study of AMT-130 can be the main basis for a Biologics License Application. This removes a major regulatory hurdle, making approval much more likely and sending QURE up 81%.
This is the core new event that directly caused the stock's massive jump and changes the company's outlook.
BLA submission planned for Q3 2026 uniQure now plans to file for approval in the third quarter of 2026, a concrete near-term step. This gives investors a clear timeline and raises confidence that the therapy could reach the market sooner than expected.
It provides a specific catalyst date and shows the company is moving quickly toward commercialization.
Analyst upgrades and fair value increase Several Wall Street firms raised price targets, with Barclays and Cantor Fitzgerald upgrading to Overweight. The modelled fair value rose 35% to about $52.56, reflecting a potential $3 billion-plus peak sales opportunity for AMT-130.
Analyst actions and valuation changes show professional investors see significantly more upside after the FDA news.
Remaining execution risks and confirmatory study Despite the rally, Goldman Sachs kept a Neutral rating, noting that the FDA will still hold a meeting to discuss the design of a confirmatory study and that durability data are needed. These steps could delay or complicate final approval.
It provides a balanced view by highlighting that not all uncertainty is removed, which could cap further gains.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.